Skip To Main Content
Philippe Antoine Bilodeau on Muck Rack

Philippe Antoine Bilodeau

As seen in: SAGE Publishing, Multiple Sclerosis and Related Disorders
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Philippe Antoine

Contact Philippe Antoine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Validity of Model for Predicting Risk of Relapse in MOGAD

|
By Philippe Antoine Bilodeau, Brian Healy, E. Ann Yeh, Gavin Giovannoni
| Multiple Sclerosis and Related Disorders Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Banwell, B. ... Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria The Lancet Neurology. 2023; 22:268-282 Preprint at 2. Cobo-Calvo, A. ... Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Ann Neurol. 2021; 89:30-41 3. Bilodeau, P.A. ...
Open in Who Shared Issue with article?

Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease

|
By Anastasia Vishnevetsky, Negar Molazadeh, Itay Lotan, Philippe Antoine Bilodeau
| SAGE Publishing
Abstract Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can cause optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis (ADEM). Immunotherapy is often used for relapsing disease, but there is variability in treatment decisions.
Open in Who Shared Issue with article?
See all 2 articles